About iridex - IRIX
IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. Its products include lasers, laser delivery and glaucoma devices, retinal surgical instruments, veterinary, and ENT. The company was founded by Eduardo Arias, Theodore A. Boutacoff, David M. Buzawa and James L. Donovan in February 1989 and is headquartered in Mountain View, CA.
IRIX At a Glance
IRIDEX Corp.
1212 Terra Bella Avenue
Mountain View, California 94043
| Phone | 1-650-940-4700 | Revenue | 52.68M | |
| Industry | Medical Specialties | Net Income | -4,437,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 8.231% | |
| Fiscal Year-end | 12 / 2026 | Employees | 93 | |
| View SEC Filings |
IRIX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.376 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -23.747 |
| Enterprise Value to Sales | 0.462 |
| Total Debt to Enterprise Value | 0.186 |
IRIX Efficiency
| Revenue/Employee | 566,397.849 |
| Income Per Employee | -47,709.677 |
| Receivables Turnover | 5.519 |
| Total Asset Turnover | 1.807 |
IRIX Liquidity
| Current Ratio | 1.912 |
| Quick Ratio | 1.315 |
| Cash Ratio | 0.456 |
IRIX Profitability
| Gross Margin | 35.888 |
| Operating Margin | -4.881 |
| Pretax Margin | -8.315 |
| Net Margin | -8.423 |
| Return on Assets | -15.225 |
| Return on Equity | -126.428 |
| Return on Total Capital | -46.933 |
| Return on Invested Capital | -70.056 |
IRIX Capital Structure
| Total Debt to Total Equity | 92.076 |
| Total Debt to Total Capital | 47.937 |
| Total Debt to Total Assets | 15.547 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 40.544 |